関連する実験動画
Updated: Jul 19, 2026

09:34
In Vivo Canine Muscle Function Assay
Published on: April 5, 2011
中性エンドペプチダースの役割 進行中の閉塞性心不全の犬における中性エンドペプチダスの役割
K B Margulies1, P L Barclay, J C Burnett
1Section of Cardiology, Temple University School of Medicine, Philadelphia, Pa 19140.
Circulation
|April 1, 1995
まとめ
中性エンドペプチダース阻害 (NEP-I) は,閉塞性心不全 (CHF) で心房内尿素因子 (ANF) に対する腎臓の反応を高めます. この戦略はナトリウムバランスを改善しますが,進化するCHFにおけるナトリウム保持を完全に解決しません.
科学分野:
- 心血管生理学 心血管の生理学
- 腎臓生理学 腎臓生理学
- 薬理学 薬理学とは
背景:
- 閉塞性心不全 (CHF) は,心房ナトリウレティック因子 (ANF) に対する腎臓の反応の低下を含む神経門機能障害を伴う.
- 中性エンドペプチダゼ24.11 (NEP) はANFを分解し,その活動はCHFで増加し,ナトリウム保持に寄与する可能性があります.
- NEPをターゲットにすることで,ANFの効果を高め,CHFの進行を緩和することができます.
研究 の 目的:
- 慢性中性エンドペプチダース阻害 (NEP-I) が,進化する結血性心不全 (CHF) の動物モデルにおいて,ANFに対する腎臓の反応に及ぼす影響を調査する.
- NEP-IがCHFの進行中にナトリウム保持と腎循環グアナシンモノフォスファート (cGMP) の生成を変化させるかどうかを判断する.
主な方法:
- ベントリキュラ・ペーシング誘発性CHFが進化している13頭の意識のある犬を活用しました.
- カンドオキサトリル (NEP-I) を6匹の犬に経口投与した.
- ベースラインおよびCHFの6日後に,外因的なANF (10マイクログラム/kgIVボルス) に対する評価応答.
- 日々の代謝研究を行い,腎臓のcGMP生成を測定した.
主要な成果:
- 慢性的なNEP-Iは,進化するCHFの犬の腎上でのナトリウム分泌とcGMP生成を増加させ,内在的なANFの腎臓活動の増加を示唆しました.
- 外因的なANFに対する腎臓ナトリウレティックとcGMPの反応は,治療されていないCHFで反応が弱まったときと異なり,CHFのNEP-Iで無傷のまま残りました.
- ANF反応とナトリウムバランスの改善にもかかわらず,慢性的なNEP-Iでは中程度の程度のナトリウム保持が進行中のCHFで持続しました.
結論:
- NEPによる酵素分解は,全身的血液動力学やANFの血濃度に関係なく,CHFにおける腎臓のANF反応を制限する.
- NEP-Iは,CHFにおける内因性および外因性ANFに対する腎臓の反応を強化する.
- NEP-Iにもかかわらず,CHFにおける持続的なナトリウム保持は,他のANF独立した抗ナトリウレット因子の貢献を示唆しています.
関連する概念動画
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

